BRÈVE

sur GENFIT (EPA:GNFT)

GENFIT: NIS2+® Included in New Clinical Guidelines for MASLD

Graphique de l'évolution du cours de l'action GENFIT (EPA:GNFT).

GENFIT, a late-stage biopharmaceutical company, announced the inclusion of its NIS2+® technology as a key tool in the latest European Clinical Practice Guidelines for managing metabolic dysfunction-associated steatotic liver disease (MASLD). The guidelines were developed by the European associations for the study of liver, diabetes, and obesity. They provide updates on prevention, screening, diagnosis, and treatment of MASLD.

Dean Hum, Chief Scientific Officer at GENFIT, stated that this inclusion is a significant recognition based on solid evidence that NIS2+® could help identify patients who may benefit from new treatments for metabolic dysfunction-associated steatohepatitis (MASH).

NIS2+® is now featured as a non-invasive method for detecting at-risk MASH, the only blood-based test mentioned for this condition. With the recent FDA approval of resmetirom and the limitations of liver biopsy in clinical practice, non-invasive panels like NIS2+® could help in selecting patients for pharmacotherapy.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de GENFIT